Free Trial
→ The Fed Just Got Kneecapped — Here’s What Happens Next (From Banyan Hill Publishing) (Ad)tc pixel
LON:SCLP

Scancell 9/11/2025 Earnings Report

Scancell logo
GBX 10.44 +0.41 (+4.09%)
As of 11:46 AM Eastern
ProfileEarnings History

Scancell EPS Results

Actual EPS
-GBX 1.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scancell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scancell Announcement Details

Quarter
Date
9/11/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Scancell Earnings Headlines

Martin Diggle Buys 3,150,000 Shares of Scancell (LON:SCLP) Stock
September 18, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30332448
Scancell Holdings: Strategic Share Acquisition by Vulpes Testudo Fund
September 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scancell-holdings-strategic-share-acquisition-by-vulpes-testudo-fund?utm_source=marketbeat.com&utm_medium=referral
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enforcing that means a $5.39 billion pot must be paid out to everyday Americans. See, virtually every AI model is built off stolen data...tc pixel
September 22 at 2:00 AM  |  Angel Publishing (Ad)
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
September 11, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scancell-reports-business-update-and-financial-results-for-the-year-ended-30-april-2025-1035135114
Scancell Holdings Sees Significant Share Acquisition by Vulpes Testudo Fund
August 4, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/scancell-holdings-sees-significant-share-acquisition-by-vulpes-testudo-fund?utm_source=marketbeat.com&utm_medium=referral
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
July 23, 2025  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2025/07/22/10226900.htm
See More Scancell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scancell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scancell and other key companies, straight to your email.

About Scancell

Scancell (LON:SCLP) (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs. Our advanced therapeutic vaccine programmes, SCOPE and ModiFY, have shown promising efficacy in Phase 2 trials, demonstrating long-term survival in metastatic melanoma and a broad range of solid tumours.

View Scancell Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles